|
Dec 3
|
Travere Therapeutics (NASDAQ:TVTX) shareholders have endured a 74% loss from investing in the stock three years ago
|
|
Sep 26
|
Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)
|
|
Sep 11
|
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Aug 8
|
News Flash: Analysts Just Made A Notable Upgrade To Their Travere Therapeutics, Inc. (NASDAQ:TVTX) Forecasts
|